On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes

large office building exterior
Eli Lilly reported its 2016 launch Lartruvo failed a phase 3 test in patients with soft tissue sarcoma. (Eli Lilly)

After patent expirations and other woes, Eli Lilly has been leaning on a stable of new drugs for growth. But after a trial failure for soft tissue sarcoma launch Lartruvo, the drugmaker is stopping promotion for the drug.

In a phase 3 trial, the drug failed to confirm an overall survival benefit for patients with advanced or metastatic soft tissue sarcoma, Lilly reported. The drug won its U.S. and European approvals based on a phase 2 trial that did show it could help patients live longer.

Now, Lartruvo is in crisis mode. Lilly is “working with global regulators to determine the appropriate next steps” for the med and is taking a pre-tax charge of $70 million to $90 million this quarter. For the year, it expects a 17-cent hit to earnings per share from the trial failure.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

That's a blow to Lilly Oncology, which had booked significant sales growth for Lartruvo. After its 2016 launch, it delivered $203 million in 2017 and $221 million in the first nine months of 2018. 

RELATED: Eli Lilly's sarcoma newcomer Lartruvo joins burgeoning oncology lineup 

And that, in turn, could interfere with Lilly’s 2019 revenue estimate of $25.3 billion to $25.8 billion, announced last month—a figure that beat average analyst expectations of $25 billion. After patent losses in recent years, including for blockbuster Cialis, the company has been counting on new launches to chip in growth.

It's also made oncology a priority. The company last week made a splash at the J.P. Morgan Healthcare Conference with its move to acquire Loxo Oncology for $8 billion. With the deal, the company gets access to the FDA-approved “tumor agnostic” cancer med Vitrakvi, which treats patients whose tumors feature a neurotrophic receptor tyrosine kinase gene fusion, regardless of location in the body. Loxo sells the drug in a partnership with Bayer.  

RELATED: Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout 

The Loxo deal also brings several pipeline meds: a follow-up TRK inhibitor, an oral BTK inhibitor and a RET inhibitor called LOXO-292 that has received an FDA breakthrough therapy designation. LOXO-292 could represent a 2020 launch opportunity, Lilly said. 

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.